Hologic Stockholders Approve Merger with Cytyc
BEDFORD, Mass., Oct. 18 / -- Hologic, Inc. today announced that its stockholders voted overwhelmingly at a Special Meeting of Stockholders to approve the transactions contemplated by Hologic's previously announced merger with Cytyc.
More than 90 percent of the shares represented at the meeting and more than 70 percent of the outstanding shares of Hologic were voted in favor of the transactions at the Hologic stockholders meeting.
"We are pleased and gratified by the strong support we have received from our stockholders," said Jack Cumming, Hologic's Chairman and Chief Executive Officer. "We are excited about bringing together two well-respected industry leaders in the women's healthcare and diagnostics marketplace, and we are eager to begin working with our colleagues at Cytyc to realize the benefits this combination will bring to stockholders, employees, physicians and their patients."
The transaction is expected to close early next week. Under the terms of the Agreement and Plan of Merger entered into on May 20, 2007, Cytyc stockholders will receive 0.52 of a share of Hologic common stock and $16.50 in cash for each share of Cytyc common stock they own for a total consideration of approximately $6.2 billion.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C- arm and extremity MRI imaging for orthopedic applications.
Source: Hologic, Inc
